News

This is part of a four-year cooperative research and development agreement (CRADA) encompassing multiple Phase I and Phase II clinical studies with correlating translational research of AFP-464 in

The technology is being used in the manufacturing of HemoBioTech’s lead product HemoTech, potentially the first viable substitute for human blood. HemoTech is composed of chemically modified bovine

James Mack, president and CEO since 1995 and chairman since 1999, has announced he will step down. The company will separate the positions of board chairman and CEO

The company expects to begin shipping immediately. This product is a generic version of AstraZeneca’s branded product, Toprol-XL. Metoprolol succinate extended-release tablets are indicated for the treatment of

Coupled together with the Situs OTW left ventricle pacing lead, this device will now allow US physicians to treat their heart failure patients with a complete Sorin Group

Mr Ellberger succeeds Fredric Price who served as Omrix’s chairman from January 2005. Mr Ellberger has been a member of the company’s board since August 2006 and was

The applications were submitted using the decentralized process with the UK serving as the reference member state. With the validation, the agencies will begin their formal review of

The interim findings from first Phase of the study suggested that the vaccine is well tolerated and immunogenic at the 15 microgram and 45 microgram dose levels. Based

The AVP III is a self-expanding nitinol mesh device and is designed to be introduced in a minimally invasive fashion through a catheter. The AVP III is under